血管生成素受体
血管生成
癌症研究
新生血管
血管生成素
下调和上调
髓样
转移
生物
基因敲除
血管内皮生长因子
癌症
医学
细胞培养
内科学
血管内皮生长因子受体
基因
遗传学
生物化学
作者
Roberta Mazzieri,Ferdinando Pucci,Davide Moi,Erika Zonari,Anna Ranghetti,Alvise Berti,Letterio S. Politi,Bernhard Gentner,Jeffrey L. Brown,Luigi Naldini,Michele De Palma
出处
期刊:Cancer Cell
[Elsevier]
日期:2011-04-01
卷期号:19 (4): 512-526
被引量:562
标识
DOI:10.1016/j.ccr.2011.02.005
摘要
Tumor-infiltrating myeloid cells convey proangiogenic programs that counteract the efficacy of antiangiogenic therapy. Here, we show that blocking angiopoietin-2 (ANG2), a TIE2 ligand and angiogenic factor expressed by activated endothelial cells (ECs), regresses the tumor vasculature and inhibits progression of late-stage, metastatic MMTV-PyMT mammary carcinomas and RIP1-Tag2 pancreatic insulinomas. ANG2 blockade did not inhibit recruitment of MRC1+ TIE2-expressing macrophages (TEMs) but impeded their upregulation of Tie2, association with blood vessels, and ability to restore angiogenesis in tumors. Conditional Tie2 gene knockdown in TEMs was sufficient to decrease tumor angiogenesis. Our findings support a model wherein the ANG2-TIE2 axis mediates cell-to-cell interactions between TEMs and ECs that are important for tumor angiogenesis and can be targeted to induce effective antitumor responses.
科研通智能强力驱动
Strongly Powered by AbleSci AI